Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...

Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...

March 23, 2012 — Results of a small phase 2B trial comparing tenecteplase with alteplase for the treatment of ischemic stroke showed better perfusion and clinical outcomes with tenecteplase when ...

Review the side-effects of Alteplase as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

Alteplase is widely used for acute stroke at a dose of 0.6 mg/kg in Asian patients, whereas the standard in Europe and the USA is 0.9 mg/kg. The ENCHANTED study did not show that 0.6 mg/kg alteplase ...

Researchers found that the percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days was 40.3 and 26.3% in the alteplase and standard medical treatment groups, ...

Patients with minor acute ischemic strokes and deficits that are not clearly disabling at presentation do not derive a benefit from IV alteplase, according to results of the PRISMS trial, which was ...